![](https://investorshub.advfn.com/uicon/8777.png?cb=1703671008)
Tuesday, April 03, 2018 9:03:04 AM
PDF]Involvement of the sigma1 (r1) receptor in the anti-amnesic, but not ...
anavex.com/files/BJP.pdf
by J Espallergues - ?2007 - ?Cited by 27 - ?Related articles
Key results: In vitro, ANAVEX1-41 was a potent muscarinic (M1>M3, M4>M2 with Ki ranging from 18 to 114 nM) and selective s1 ligand (s1, Ki ¼ 44 nM; s2, Ki ¼ 4 µM). In mice, ANAVEX1-41 failed to affect learning when injected alone (0.03–. 1 mg kg?1), but attenuated scopolamine-induced amnesia with a bell-shaped ...
Anti-amnesic and neuroprotective potentials of aminotetrahydrofuran ...
anavex.com/files/ICAD_2008_Abstract_Anavex.pdf
affinity for M1, M2, M4 muscarinic acetylcholine receptors and s1 protein. Both compounds are potent anti-amnesic drugs alleviating learning impairments observed in mice after the central (i.c.v.) injection of amyloid ß25-35 peptide (Aß25-35). Central administration of Aß25-. 35 induces within one week histological and ...
p2.216 anti-amnestic and neuroprotective activities of anavex2-73
anavex.com/files/ICAD%202009%20POSTER%20216.pdf
Contact aliev30@gmail.com. Background: Tetrahydro-N,N-Mmethyl-2,2diphenyl -furanmethanamine (ANAVEX2-73) is a new sigma-. 1 receptor (SIR) ligand, with a sur-micro-molar affinity (IC50= 860 Nm & Xc Ki= 710 nm) and low affinities (IC50=3.3-5.2µM) for M I -M4 muscarinic receptors. No affinity was found for sigma-2.
[PDF]Blockade of Tau Hyperphosphorylation and A&beta - Anavex Life ...
www.anavex.com/my_uploads/Blockade-of-Tau-Hyperphosphorylation-and.pdf
by V Lahmy - ?2013 - ?Cited by 62 - ?Related articles
Apr 3, 2013 - hydrochloride (ANAVEX2-73) presents such a mixed s1/muscarinic receptor profile, with a moderate affinity range. Indeed, the compound has a sub-micromolar affinity for the s1 receptor (IC50 ¼ 0.86 µM) and micromolar affini- ties for muscarinic human recombinant M1—M4 receptors. (IC50 ¼ 3.3–5.2µM), ...
Inserm - Anavex Life Sciences
anavex.com/files/Maurice_Poster_Montpellier_May_2007.pdf
behavioral effects of ANAVEX2-73 particularly at the 1000 µg/kg dose of compound. Both ANAVEX1-41 and ANAVEX2-73 are thus promising neuroprotective compounds in this AD animal model. The mechanism of the combined activity at. M1/M2/M4 muscarinic receptors and s1 receptors must be investigated further.
Antiamnesic and Neuroprotective Effects of the ... - Semantic Scholar
anavex.com/files/Neuropsychopharmacology%202008.pdf#13
by V Villard - ?2008 - ?Cited by 73 - ?Related articles
ANAVEX1-41 is a new aminotetrahydrofuran derivative. (Vamvakides, 2002; Espallergues et al, 2007) acting as a s1 protein activator, with a high affinity (44 nM) and selectivity. The CEREP profile of the compound showed that it also presents nanomolar affinities (18–114nM) for muscarinic receptors (M1>M3, M4>M2), ...
[PDF]1207 AAIC Tangui Poster - Anavex Life Sciences
www.anavex.com/my_uploads/Neuroprotective-efficacy-of-Anavex-2-73.pdf
by T Maurice
muscarinic M1—M4 receptors (IC50 = 3.3 - 5.2 µ?), sodium channel site 2 (IC50 = 5.1 µM), and. NMDA receptors (IC50 = 8.0 µ?). ?. We showed the neuroprotective potential of ANAVEX2-73 against amyloid toxicity in mice. In particular, ANAVEX2-73 attenuated the oxidative stress, caspases induction, cellular loss and ...
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM